Refractory hypokalemia during barbiturate coma therapy used for treating refractory intracranial hypertension in

Wan Mohd Nazaruddin Wan Hassan1, Nazuha Mohd Najid1, Halimatun Sa'adiah Muslim1

  • 1Department of Anaesthesiology, School of Medical Sciences and P3 Neuro Center, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.

Insights

Barbiturate coma therapy can cause dangerous low potassium levels. This case report details managing this rare complication in a patient undergoing thiopentone treatment for high intracranial pressure.

Area of Science:

  • Neuroscience
  • Critical Care Medicine
  • Pharmacology

Background:

  • Barbiturate coma therapy (BCT) is a critical intervention for refractory intracranial hypertension (ICP) when standard treatments fail.
  • BCT effectively reduces cerebral blood flow, oxygen consumption, and ICP.
  • However, BCT is associated with significant complications, including electrolyte imbalances.

Observation:

  • Refractory hypokalemia (low potassium) is an underreported yet life-threatening complication of BCT.
  • This complication can paradoxically lead to hyperkalemia (high potassium) upon abrupt discontinuation of the therapy.
  • We present a case of managing refractory hypokalemia during thiopentone-induced BCT in a patient who underwent decompressive craniectomy.

Findings:

  • The patient developed persistent hypokalemia requiring intensive management.
  • Careful monitoring and electrolyte correction were crucial to prevent rebound hyperkalemia.
  • Successful management involved a tailored approach to BCT and potassium replacement.

Implications:

  • Highlights the importance of vigilant electrolyte monitoring during BCT.
  • Suggests a need for standardized protocols for managing hypokalemia in patients receiving BCT.
  • Informs clinical practice regarding the safe use of thiopentone for intracranial pressure management.

Related Concept Videos

Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
1.5K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.8K
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
502
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
739
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K